Misplaced Pages

This is an old revision of this page, as edited by Lenny Kaufman (talk | contribs) at 00:03, 4 January 2013 (→Prostaglandin D2: completing reversion). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

In the United States, Baldness treatment is a $1 billion per year industry. Past the early 20s, the incidence of balding or pattern hair loss in males is roughly equivalent to chronological age. Thus, by age 50, roughly half of men experience male pattern baldness (MPB).) Beginning in the 1980s, drug therapy gives a treatment option for baldness in both men and women. For example, increased understanding of the role of dihydrotestosterone (DHT) in male and female pattern baldness has led to targeted intervention to prevent this hormone from acting on scalp androgen receptors. Like many other medical conditions, baldness can be treated, but not cured. Moreover, experts warn that many treatments marketed as hair loss cures are ineffective aside from the placebo effect.

Lifestyle modification

Several genetic factors determine susceptibility to male pattern baldness (MPB). These factors include androgen receptor polymorphisms and scalp 5-alpha-reductase levels. Other variables include androgen receptor density and distribution in the scalp. Vigorous aerobic exercise daily, as opposed to short workout periods designed to raise androgen levels and build muscle or more sporadic exercise, and a diet which is adequate, yet more moderate in fat and total calorie intake, have been shown to reduce baseline insulin levels as well as baseline total and free testosterone.

Lower insulin levels and reduced stress both result in raised levels of sex hormone-binding globulin (SHBG). SHBG binds to testosterone. Only free testosterone improves muscle growth and insulin sensitivity, but free testosterone can also be converted to the ineffective (regarding insulin sensitivity) DHT. The levels of free androgens and not of total androgens are relevant to the levels of DHT in the scalp and the progression of male pattern baldness.

Androgenic alopecia occasionally correlates with metabolic syndrome. This may be because typically bald men have low testosterone levels (hypogonadism) which can easily trigger also diabetes mellitus and erectile dysfunction. Medically increasing androgen levels improves this condition, demonstrating that androgens do not cause metabolic syndrome. Instead, high insulin levels (and possibly chronic inflammation) seem the likely link in the demonstrated correlation between baldness and metabolic syndrome. This reinforces the notion that behaviors which help to keep insulin levels low and reduce chronic inflammation might also help to preserve hair.

Head cooling

Machines for cooling of the scalp are available and prescribed to patients to prevent hair loss due to chemotherapy.

Medications

The U.S. Food and Drug Administration (FDA) has approved two medications for the treatment of male pattern baldness: minoxidil (Rogaine) and finasteride (Propecia).

Both agents are recommended as first-line treatment for male pattern baldness. They may also be used simultaneously when hair loss is progressive or further regrowth is desired after 12 months.

Minoxidil and kopexil

Minoxidil (Rogaine) is a vasodilator. It was originally used as the oral drug Loniten to treat high blood pressure. However, minoxidil was discovered to have the side effects of hair growth and reversing baldness. Consequently, in the 1980s, Upjohn Corporation received FDA approval to market a topical solution that contained 2% minoxidil to be used to treat baldness and hair loss as Rogaine, marketed as Regaine outside the USA.

Objective evidence shows that minoxidil is effective for treatment of male-pattern hair loss in both the frontal and the vertex areas of the scalp. At the conclusion of a 48-week study, improvements were seen in the vertex area regions of 51% of men using 5% minoxidil, 42% using 2% minoxidil, and 13% of placebo users. Among these men, moderate to great increases in hair growth were seen in the frontal scalp regions of 19% of men using 5% minoxidil, 10% using 2% minoxidil, and 3% of placebo users.

The mechanism of action of minoxidil is not known. Its action as a vasodilator may involve opening vascular smooth muscle potassium channels (K-channels), perhaps through mimicking the most important natural vasodilator, nitric oxide, whose structure minoxidil incorporates. As it wakes up dormant telogen phase follicles, this agent may cause loss-phase hairs to shed earlier than they normally would. This "shed" is generally followed by the growth of new, thicker hairs. As the hair-growth-stimulating effect is temporary and does not seem to change the follicle in any other way, minoxidil needs to be applied regularly (once or twice daily) for hair gained to be maintained.

A slightly changed derivative of minoxidil missing one piperidine substituent is kopexil (brand name Aminexil); for kopexil there is – until now – no proof of therapeutic effect against androgenic alopecia.

Finasteride

Finasteride (marketed by Merck under the trade names Propecia and Proscar) is a type-2 isoenzyme 5 alpha-reductase inhibitor .

It was originally FDA approved for treatment of benign prostatic hyperplasia (BPH) and works by binding to 5-alpha-reductase, the enzyme responsible for the conversion of free testosterone to DHT.

Merck sought to find the smallest effective quantity of finasteride and test its long-term effects on 1,553 men between ages 18 and 41 with mildly to moderately thinning hair. Based on their research, 1 mg/day was selected, and after two years of daily treatment, over 83% of the 1,553 men experiencing male hair loss had actually maintained or increased their hair count from baseline. Visual assessments concluded that over 80% had improved appearances.

In 1997, finasteride was approved by the US FDA for the casual treatment of male pattern baldness. A 5-year study revealed that 9 of 10 men taking finasteride (1 mg/day) experienced visible results (42% of men taking Propecia experienced no further hair loss while 48% experienced no further hair loss and hair regrowth). In clinical studies, finasteride, like minoxidil, was shown to work on both the crown area and the hairline area, but is most successful in the crown area.

Dutasteride

Dutasteride is a dual 5-a reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT).

Dutasteride inhibits both isoforms of 5-alpha reductase, type I and type II, whereas finasteride only inhibits type II.

Dutasteride (trademark name Avodart, manufactured by GlaxoSmithKline) is approved for the treatment of benign prostatic hyperplasia (BPH).

Phase I and II clinical trials for dutasteride as a hair loss drug were undertaken, but called off in late 2002, with reasons for termination unreported.

The phase II results indicated that dutasteride at both 0.5 mg and 2.5 mg/day generated a superior hair count to finasteride 5 mg at 12 and 24 weeks.

Phase II study results at 24 weeks:

• Placebo: – 32.3

• Dutasteride 0.5 mg: + 94.6 hairs

• Dutasteride 2.5 mg: + 109.6 hairs

GlaxoSmithKline ran a phase III, six month study in Korea to test the safety, tolerability and effectiveness of a once-daily dose of dutasteride (0.5 mg) in male pattern baldness (MPB) at the vertex of the scalp (types IIIV, IV and V on the Hamilton-Norwood scale). The study was completed in January 2009. Future intentions by GlaxoSmithKline to continue or abandon plans for FDA approval of dutasteride in treatment of MPB remain unknown.

Hair transplantation

A medical hair transplant involves using small grafts of naturally-occurring units of one to four hairs, called follicular units, to move hair-producing follicles to balding areas of the hair restoration patient's scalp. These follicular units are surgically implanted in the scalp in very close proximity to one another and in large numbers. The grafts are obtained in one or both of the two primary methods of surgical extraction, Follicular Unit Transplantation (FUT) or Follicular Unit Extraction (FUE). In FUT, a strip of skin containing many follicular units is extracted from the patient and then dissected under a stereoscopic dissecting microscope. Once dissected into individual follicular unit grafts, the surgeon implants the grafts into small incisions, called recipient sites, in the recipient area of the patient's scalp. According to the new approach the roots of the hair are extracted from the "donor", and then literally cut into tiny strips, for transplantation. Bald patches on the scalp are isolated and given the donor strip, which is two to three millimeters thick only. When the transaction is completed, the patient should wear a head bandage for the next two days. This will allow the scalp to treat not weakened, and increase the chances of success.

Laser therapy

There are devices that use low-level laser therapy (LLLT) that claim to stimulate hair growth through "photo-biostimulation" of the hair follicles, although with limited evidence of benefit or safety.

Research

Caffeine

Caffeine has been identified as a stimulator of human hair growth in vitro, and reduced testosterone-induced follicle growth suppression. It has been demonstrated that the addition of caffeine to a shampoo-formulation is effective in administering caffeine to the hair follicles in the scalp. Further research must be done to evaluate the efficacy and adequate dosage of caffeine in the treatment of androgenetic alopecia. A spray made with coffee beans is claimed by the UK pharmacy chain Boots to prevent age-related hair loss in women.

Genetics

In February 2008 researchers at the University of Bonn announced they have found the genetic basis of two distinct forms of inherited hair loss, opening a broad path to treatments for baldness. They found that a gene, P2RY5, causes a rare, inherited form of hair loss called hypotrichosis simplex. It is the first receptor in humans known to play a role in hair growth. The fact that any receptor plays a specific role in hair growth was previously unknown to scientists and they are now attempting to gather more genetic and biological data.

In May 2009, researchers in Japan identified a gene, SOX21, that appears to determine cyclical hair loss in mice. The researchers also believe it may be responsible for hair loss, or alopecia, in people.

Through 2006, Curis and Procter & Gamble spent $1,000,000 on a hair growth program focused on the potential development of a topical hedgehog agonist for hair growth disorders such as male pattern baldness and female hair loss. Because the agent did not meet the proper safety standards. , the hair loss research program was shut down in May 2007

Spin labels and Pyridine-N-oxides

Originally patented for treatment of pattern hair loss and used off-label for this disorder, in animal models, the nitroxide spin labels TEMPO and TEMPOL also enhance hair regrowth following radiation. There is currently a National Cancer Institute-sponsored clinical trial for TEMPOL in radiation alopecia. Related pyridine-N-Oxides, such as nicotinic acid-N-oxide or "NANO" are also patented and used for hair loss treatment.

Hair multiplication

Stem cells and dermal papilla cells have been discovered in hair follicles. Research on these follicular cells may lead to successes in treating baldness through hair multiplication (HM), also known as hair cloning. HM is being developed by ARI (Aderans Research Institute, a Japanese owned company in the USA).

In 2008, Intercytex, a company in Manchester (UK), announced positive results of a Phase II trial for a form of cloning hair follicles from the back of the neck, multiplying them and then reimplanting the cells into the scalp. The initial testing resulted in at least two thirds of male patients regrowing hair. As of 2009, the company estimates this treatment will take "a number of years to complete" Phase III trials before it can go to market. However, after failing to achieve subsequent success in their trials, the company announced discontinuation of its hair multiplication project in January 2010 with intention to sell off its assets and research. On March 25, 2010 Aderans Research Institute Inc. (ARI) announced it acquired key technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc). ARI is currently conducting Phase II clinical trials in cities throughout the U.S.

In December 2010, scientists at the Berlin Technical University in Germany revealed they had grown the world's first artificial hair follicles from stem cells. Research leader Dr Roland Lauster said within five years millions of hair-loss sufferers could grow new hair from their own stem cells and have it implanted into their bald spots. He also announced that preparations for clinical trials were "already in motion".

Replicel Life Sciences is another company pursuing an effective treatment for hairloss. In their first human clinical trial, Replicel was able to regenerate 19.6% percent of hair on one patient's treated area. Replicel is using a hair multiplication technique different from Aderans, using dermal sheath cup cells instead of dermal papilla cells. Replicel is looking forward for the Phase II at the end of 2012.

In April 2012, a research group headed by Professor Takashi Tsuji demonstrated "functional hair regeneration from adult stem cells", a substantial advance in the development of the next generation of "organ replacement regenerative therapies". This procedure has only been tested on mice; human clinical trials have not been announced.

WNT protein introduction

In May 2007, U.S. company Follica Inc, announced they had licensed technology from the University of Pennsylvania which can regenerate hair follicles by reawakening genes which were once active only in the embryo stage of human development. Skin apparently can be brought back to this embryonic state when a wound is healing. Hair growth was discovered in the skin wounds of mice when Wnt proteins were introduced to the site. Development of a human treatment is expected to take several years.

In 2011, the natural oral minoxidil mimic TRX2 was released on the market. Similar to minoxidil, its mechanism of action may involve the opening of potassium channels. The product is a dietary supplement, not a drug, and hence is not FDA-approved.

Grateloupia elliptica

In 2012, a Korean scientific study showed that Grateloupia elliptica, a red seaweed native to Jeju Island, South Korea, has the potential to treat androgenic alopecia as well as alopecia areata.

Prostaglandin D2

In August 2012, Scientists at the University of Pennsylvania announced that they had discovered an lipid which caused baldness. They found that the lipid Prostaglandin D2 (PGD2) was found to be present on the scalp of balding men at far higher levels than normal, preventing hair follicles from maturing and therefore stopping them from working and growing hair. Dr. George Cotsarelis and his dermatological team at the University say that they are in talks with several pharmaceutical companies about developing treatments which could be available in two years.

L-Carnitine-Tartrate

A study performed by German scientists showed that L-Carntine-tartrate induces hair growth in humans. TRX2, a product released in 2011 by Oxford scientists, lists L-Carnitine-Tartrate as its main ingredient.

References

1. Proctor PH. Hair-raising. The latest news on male-pattern baldness. Adv Nurse Pract. 1999 Apr;7(4):39-42, 83. Review. PubMed PMID 10382384.
2. Whyche, Stephanie. "The Bald Truth About Hair Loss in Young Men". Retrieved July 26, 2006.
3. ^ "Propecia & Rogaine for Treating Male Pattern Baldness". Webmd.com. Retrieved May 19, 2010.
4. Daly W, Seegers CA, Rubin DA, Dobridge JD, Hackney AC (2005). "Relationship between stress hormones and testosterone with prolonged endurance exercise". European Journal of Applied Physiology. 93 (4): 375–80. doi:10.1007/s00421-004-1223-1. PMID 15618989. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
5. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH (2002). "Prostate cancer: another aspect of the insulin-resistance syndrome?". Obesity Reviews. 3 (4): 303–8. doi:10.1046/j.1467-789X.2002.00081.x. PMID 12458975. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
6. Barnard RJ, Aronson WJ (2005). "Preclinical models relevant to diet, exercise, and cancer risk". Recent ZIMHATA ncer Research. 166: 47–61. doi:10.1007/3-540-26980-0_4. PMID 15648182.
7. http://www3.interscience.wiley.com/cgi-bin/fulltext/121568539/PDFSTART?CRETRY=1&SRETRY=0
8. Joffe HV, Ridker PM, Manson JE, Cook NR, Buring JE, Rexrode KM (2006). "Sex hormone-binding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular disease". Annals of Epidemiology. 16 (2): 105–12. doi:10.1016/j.annepidem.2005.07.055. PMID 16216530. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
9. Cikim AS, Ozbey N, Sencer E, Molvalilar S, Orhan Y (2004). "Associations among sex hormone binding globulin concentrations and characteristics of the metabolic syndrome in obese women". Diabetes, Nutrition & Metabolism. 17 (5): 290–5. PMID 16295051. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
10. Heald AH, Anderson SG, Ivison F; et al. (2005). "Low sex hormone binding globulin is a potential marker for the metabolic syndrome in different ethnic groups". Experimental and Clinical Endocrinology & Diabetes. 113 (9): 522–8. doi:10.1055/s-2005-865807. PMID 16235154. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
11. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 23187775, please use {{cite journal}} with |pmid=23187775 instead.
12. "FDA's Role" (PDF). Fda.gov. June 23, 2009. Retrieved May 19, 2010.
13. Beyond the Vertex – Objective evidence shows minoxidil's frontal-scalp performance | ModernMedicine
14. Proctor, P, Endothelium-Derived Relaxing Factor and Minoxidil: Active Mechanisms in Hair Growth, Archives in Dermatology, vol 125, August, 1989
15. Jasek, W, ed. (2007). Austria-Codex (in German). Vol. 4 (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. p. 9673. ISBN 978-3-85200-181-4.
16. Wolfgang Raab: Haarerkrankungen in Der Dermatologischen Praxis, p. 82, at Google Books (German).
17. Barth, J (2000). "Should men still go bald gracefully?". The Lancet. 355 (9199): 161–2. doi:10.1016/S0140-6736(99)00412-2. PMID 10675111. {{cite journal}}: Unknown parameter |laysource= ignored (help); Unknown parameter |laysummary= ignored (help)
18. Proof of results with PROPECIA
19. Leyden J, Dunlap F, Miller B; et al. (1999). "Finasteride in the treatment of men with frontal male pattern hair loss". J. Am. Acad. Dermatol. 40 (6 Pt 1): 930–7. doi:10.1016/S0190-9622(99)70081-2. PMID 10365924. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
20. Avodart 0.5 mg soft capsules | SPC from the eMC
21. Olsen EA, Hordinsky M, Whiting D; et al. (2006). "The importance of dual 5alpha-reductase inhibition in the treatment of MPB: results of a randomized placebo-controlled study of dutasteride versus finasteride". J Am Acad Dermatol. 55 (6): 1014–23. doi:10.1016/j.jaad.2006.05.007. PMID 17110217. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
22. Clinical trial number NCT00441116 at ClinicalTrials.gov
23. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study | Journal of the American Academy of Dermatology (JAAD)
25. Template:! cite news
26. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 20689478, please use {{cite journal}} with |pmid=20689478 instead.
27. Fischer TW, Hipler UC, Elsner P (2007). "Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro". International Journal of Dermatology. 46 (1): 27–35. doi:10.1111/j.1365-4632.2007.03119.x. PMID 17214716. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
28. Otberg N, Teichmann A, Rasuljev U, Sinkgraven R, Sterry W, Lademann J (2007). "Follicular penetration of topically applied caffeine via a shampoo formulation". Skin Pharmacology and Physiology. 20 (4): 195–8. doi:10.1159/000101389. PMID 17396054.{{cite journal}}: CS1 maint: multiple names: authors list (link)
29. "Spray that can stop a woman's hair from thinning | Mail Online". Daily Mail. London. June 9, 2007. Retrieved May 19, 2010.
30. "Scientists identify gene that may explain hair loss | Reuters". Reuters UK. May 25, 2009. Retrieved May 19, 2010.
31. Procter & Gamble (2005). "Curis and Procter & Gamble Enter into R&D Agreement for Hair Growth Program". Archived from the original on August 22, 2006. Retrieved August 24, 2006. {{cite news}}: Unknown parameter |month= ignored (help)
32. P Proctor, US Patent 5,352,442 Topical tempo
33. A Phase I Study of Topical Tempol for the Prevention of Alopecia Induced by Whole Brain Radiotherapy | American Association for Cancer Research
34. Topical pyridine N-oxides,US Patent #5,472,687
35. "Hair Cloning Nears Reality as Baldness Cure". Webmd.com. November 4, 2004. Retrieved August 10, 2006.
36. "Big Baldness Breakthrough?". Associated Press. March 15, 2004. Archived from the original on May 25, 2006. Retrieved August 10, 2006.
37. "ICX-TRC – Frequently Asked Questions". Intercytex. March 22, 2010. Retrieved May 19, 2010.
38. "Intercytex Discontinues its Hair Multiplication Development Operations | Hair Loss Q & A". Regrowhair.com. January 7, 2010. Retrieved May 19, 2010.
39. http://www.aderansresearch.com/pdfs/PR_ARI_US032510.pdf
40. Follicle Neogenesis, Bio Engineered Hair Loss Solution | Aderans Research
41. Bates, Claire (December 20, 2010). "Cure for baldness on the horizon as scientists grow world's first hair follicles using stem cells". Daily Mail. London.
42. http://www.replicel.com/wp-content/uploads/2012/RepliCel-AGM-Presentation-June-11-12.pdf
43. http://www.sciencedaily.com/releases/2012/04/120418095011.htm
44. First Demonstration of New Hair Follicle Generation in an Animal Model | PENN Medicine News
45. Study offers hope of baldness remedy | msnbc.com
46. Tyler, Richard (January 9, 2011). "Thomas Whitfield's German roots help hair loss product launch". The Daily Telegraph. Retrieved July 23, 2012.
47. ^ Edwards, Jim (January 12, 2011). "Pharma's 4 Best Shots at a Cure for Baldness" (Web). CBSNews.com. CBS News. Retrieved August 1, 2012. it's actually just another dietary supplement and as such is not approved by the FDA. Cite error: The named reference "CBS" was defined multiple times with different content (see the help page).
48. "Minoxidil Alternatives" (Web). MPB Research. Retrieved August 1, 2012.
49. Kang II, J., Kim, S.-C., Han, S.-C., Hong, H.-J., Jeon, Y.-J., Kim, B., Koh, Y.-S., Yoo, E.-S., Kang, H.-K. Hair-loss preventing effect of Grateloupia elliptica (2012) Biomolecules and Therapeutics, 20(1), pp. 118–120.
50. Nguyen, H., Kim, S.M. (2012). Antioxidative, anticholinesterase and antityrosinase activities of the red alga Grateloupia lancifolia extracts. African Journal of Biotechnology, 11(39), pp. 9457–9467 (May 15). Retrieved on 2012-06-14.
51. http://www.dailymail.co.uk/news/article-2190544/Baldness-cure-reverses-genetics-market-years.html
52. http://www.telegraph.co.uk/health/healthnews/9485807/Baldness-cure-could-be-on-shelves-in-two-years.html
53. http://www.nytimes.com/2012/07/29/business/baldness-battle-fought-in-the-follicle.html
54. Foitzik, K., Hoting, E., Förster, T., Pertile, P. and Paus, R. (2007). "L-Carnitine–L-tartrate promotes human hair growth in vitro". Experimental Dermatology. 16: 936–945. (11): 936–945. doi:10.1111/j.1600-0625.2007.00611.x. {{cite journal}}: |access-date= requires |url= (help); |format= requires |url= (help); External link in |ref= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

External links

• The Trichological Society
• How Hair Replacement Works
• International Society of Hair Restoration Surgery
• "Medical Treatments for Balding in Men", April 1999, American Family Physician (medical journal)
• Health Alternatives: zinc, silica, methylsulphonylmethane (MSM) and cod-liver oil, to slow down the process.

• Dermatologic procedures